Exelixis Inc

Find Ratings Reports
EXEL : NASDAQ : Health Care
$21.28 -0.09 | -0.42%
Today's Range: 21.2 - 21.92
Avg. Daily Volume: 5266600.0
03/28/17 - 3:59 PM ET

Financial Analysis

EXELIXIS INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. EXELIXIS INC has strong liquidity. Currently, the Quick Ratio is 1.71 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 185.63% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.

Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)77.589.94
EBITDA ($mil)39.17-31.36
EBIT ($mil)38.93-31.7
Net Income ($mil)35.12-41.57

Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)419.8167.06
Total Assets ($mil)597.54332.34
Total Debt ($mil)189.12381.44
Equity ($mil)89.32-104.3

Profitability Q4 FY16 Q4 FY15
Gross Profit Margin50.49-315.53
EBITDA Margin50.49-315.52
Operating Margin50.17-318.98
Sales Turnover0.320.11
Return on Assets-11.75-48.66
Return on Equity-78.620.0
Debt Q4 FY16 Q4 FY15
Current Ratio1.743.42
Interest Expense4.4910.18
Interest Coverage8.68-3.11

Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)289.92227.96
Div / share0.00.0
Book value / share0.31-0.46
Institutional Own % n/a n/a
Avg Daily Volume5281830.06863105.0


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 65.94 indicates a significant premium versus the S&P 500 average of 2.93 and a significant premium versus the industry average of 11.85. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, EXELIXIS INC proves to trade at a premium to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
EXEL NM Peers 38.87   EXEL 28.54 Peers 22.28

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

EXEL's P/E is negative making this valuation measure meaningless.


Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

EXEL is trading at a significant premium to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
EXEL 44.15 Peers 58.77   EXEL NA Peers 0.49

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

EXEL is trading at a significant premium to its peers.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
EXEL 65.94 Peers 11.85   EXEL 58.45 Peers 165.61

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

EXEL is trading at a significant premium to its peers.


Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, EXEL is expected to significantly trail its peers on the basis of its earnings growth rate.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
EXEL 30.76 Peers 256.31   EXEL 415.04 Peers 609.16

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

EXEL is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

EXEL significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades